Automate Your Wheel Strategy on INSM
With Tiblio's Option Bot, you can configure your own wheel strategy including INSM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INSM
- Rev/Share 2.111
- Book/Share 4.4653
- PB 46.5297
- Debt/Equity 0.788
- CurrentRatio 4.6303
- ROIC -0.6243
- MktCap 44311828654.0
- FreeCF/Share -4.2791
- PFCF -48.9017
- PE -37.1649
- Debt/Assets 0.3156
- DivYield 0
- ROE -1.8355
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | INSM | Cantor Fitzgerald | -- | Overweight | -- | $192 | Oct. 28, 2025 |
| Initiation | INSM | Wells Fargo | -- | Overweight | -- | $171 | Oct. 20, 2025 |
| Initiation | INSM | William Blair | -- | Outperform | -- | -- | Aug. 20, 2025 |
| Downgrade | INSM | Morgan Stanley | Overweight | Equal Weight | -- | $126 | Aug. 13, 2025 |
| Initiation | INSM | Jefferies | -- | Buy | -- | $105 | May 13, 2025 |
| Initiation | INSM | RBC Capital Mkts | -- | Outperform | -- | $100 | Feb. 25, 2025 |
News
Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
—FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025— BRIDGEWATER, N.J. , Feb. 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it does not currently plan to hold an advisory committee meeting to discuss the New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis.
Read More
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Read More
Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance of $405 Million to $425 Million, Reflecting Double-Digit Growth Compared to 2024— —NDA for Brensocatib in Patients with Bronchiectasis Accepted by FDA and Granted Priority Review with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH, Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP, and Phase 3 ENCORE Study of …
Read More
Insmed To Present at March 2025 Investor Conferences
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
BRIDGEWATER, N.J. , Feb. 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 45th Annual TD Cowen Healthcare Conference in Boston, on Monday, March 3, 2025, at 9:10 a.m.
Read More
About Insmed Incorporated (INSM)
- IPO Date 2000-06-01
- Website https://www.insmed.com
- Industry Medical - Pharmaceuticals
- CEO William H. Lewis
- Employees 1271